Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Date:
Thursday, August 5, 2021
Summary:
During the blinded, controlled period, 15 BNT162b2 (VACCINATED) and 14 placebo recipients died; during the open-label period, 3 BNT162b2 and 2 original placebo recipients who received BNT162b2 after unblinding died. None of these deaths were considered related to BNT162b2 by investigators. Causes of death were balanced between BNT162b2 and placebo groups (Table S4).
- 1151 reads